Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 16:14:35 05/10/2021 BST			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

06-18	Cosmos Health Inc. Expands AI Automation and Facility Capacity	CI
06-17	Cosmos Health Launches Premium Korean-Developed Collagen-Based Skincare Brand in the United States	CI

Market Cap	11.57M 10.09M 9.34M 8.75M 16.4M 1.09B 16.5M 111M 42.95M 537M 43.43M 42.5M 1.87B	P/E 2026 *	21.3x	P/E 2027 *	3.04x
Enterprise Value	11.57M 10.09M 9.34M 8.75M 16.4M 1.09B 16.5M 111M 42.95M 537M 43.43M 42.5M 1.87B	EV / Sales 2026 *	0.13x	EV / Sales 2027 *	0.1x
Free-Float	66.2%	Yield 2026 *	-	Yield 2027 *	-

06-18	Cosmos Health Inc. Expands AI Automation and Facility Capacity	CI
06-17	Cosmos Health Launches Premium Korean-Developed Collagen-Based Skincare Brand in the United States	CI
06-15	Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States	CI
06-12	Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines	MT
06-11	Cosmos Health Signs Letter of Intent to Buy Doc Pharma	MT
06-10	Cosmos Health Unit Signs 3-Year Manufacturing Deal With Verisfield	MT
06-08	Cosmos Health Unit Acquires Patent Application From Cloudpharm	MT
06-05	Cosmos Health Inc. Announces U.S. Launch of Oliv18 Targeting Cardiovascular and Antioxidant Categories	CI
06-01	Cosmos Health Inc. Enters USD 69 Billion Global Animal Health Industry With Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 And EN 1657	CI
05-26	Cosmos Health targets $200 mln revenue, $44 mln adjusted EBITDA by 2029	RE
05-26	Cosmos Health Inc. Provides Earnings Guidance for the Year 2026, 2027, 2028 and 2029	CI
05-20	Cosmos Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule	MT

06-18	CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity	GL
06-17	Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States	GL
06-17	Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products	GL
06-15	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	GL
06-15	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	AQ

Cosmos Holdings Inc. Share Price OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

29/11/24	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
28/11/24	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
05/12/22	Pelè non è in cure palliative - figlia
01/12/22	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	25/02/2016
George Terzis DFI	Director of Finance/CFO	44	10/11/2020
Nikolaos Bardakis COO	Chief Operating Officer	-	31/01/2023

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	59	12/01/2014
Grigorios Siokas CHM	Chairman	60	25/02/2016
John Hoidas BRD	Director/Board Member	60	17/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	11.57M
MCKESSON CORPORATION	-3.74%	-4.26%	+2.98%	+84.79%	87.88B
CARDINAL HEALTH, INC.	-1.99%	-0.93%	+34.08%	+143.04%	51.94B
SIGMA HEALTHCARE LIMITED	-1.78%	+4.55%	-14.02%	+219.08%	22.26B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-1.24%	-2.63%	-9.19%	-25.62%	7.96B
HUADONG MEDICINE CO., LTD	+2.31%	-2.65%	-31.18%	-33.94%	7.34B
SINOPHARM GROUP CO. LTD.	-2.73%	-3.65%	-10.39%	-33.41%	6.52B
H. LUNDBECK A/S	-1.38%	-4.99%	+13.44%	+16.30%	6.16B
GALENICA AG	+1.32%	-0.88%	-2.26%	+18.26%	5.2B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+1.47%	+0.84%	-4.36%	-13.81%	3.56B
Average	-1.34%	-1.55%	-2.32%	+41.63%	22.09B
Weighted average by Cap.	-2.41%	-1.96%	+7.07%	+96.73%

	2026 *	2027 *
Net sales	87.3M 76.12M 70.5M 65.99M 124M 8.24B 125M 836M 324M 4.05B 328M 321M 14.08B	111M 96.61M 89.47M 83.76M 157M 10.45B 158M 1.06B 411M 5.15B 416M 407M 17.87B
Net income	-	-
Net Debt	-	-